Efficacy of Ruxolitinib in the management of chronic GVHD

Basit Öğe Kaydı
dc.contributor.authorGiden, Asli Odabasi
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorHidayet, Emine
dc.contributor.authorBerber, Ilhami
dc.contributor.authorTiryaki, Tarik Onur
dc.contributor.authorZorlu, Tugba
dc.date.accessioned2026-04-04T13:34:50Z
dc.date.available2026-04-04T13:34:50Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractObjectives: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for hematological diseases, with success rates improving due to advancements in conditioning regimens and new anti-graft versus host disease (GVHD) drugs. Ruxolitinib, an oral selective Janus kinase (JAK) 1 and 2 inhibitor has been used to mitigate the effects of various inflammatory and myeloproliferative syndromes, given the JAK kinase pathway's central role in cytokine signaling during inflammatory and immune processes. In this study we aimed to assess ruxolitinib's efficacy in patients with chronic GVHD (cGVHD). Material and methods: This retrospective observational multi-center study involved 50 patients diagnosed with cGVHD after allo-HSCT in Turkey, who were treated with ruxolitinib between April 2018 and March 2024. Results: At the time of initiation of ruxolitinib treatment, most patients had severe cGVHD (n = 29, 58 %). The overall response rate at 6 months of ruxolitinib treatment was observed in 34 patients (68 %), including 6 patients (12 %) with complete responses and 28 patients (56 %) with partial responses, while 7 patients (14 %) experienced treatment failure. ECOG (2-4) performance status was established as an independent risk factor for adverse outcomes [p = 0.029, HR 3.492 (95 % CI: 1.139-10.705)]. At the two-year follow-up, the estimated survival rate was 52 %. Conclusion: Ruxolitinib is safe and effective in the real-world setting for treating cGVHD, showing remission rates comparable to clinical trials. Further research with extended follow-up is necessary to confirm these findings, optimize dosing, and establish the best tapering strategies for responders.
dc.identifier.doi10.1016/j.transci.2024.104053
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1
dc.identifier.orcid0000-0003-3312-8476
dc.identifier.orcid0000-0001-6872-3780
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.pmid39708419
dc.identifier.scopus2-s2.0-85212557785
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2024.104053
dc.identifier.urihttps://hdl.handle.net/11616/109410
dc.identifier.volume64
dc.identifier.wosWOS:001392845800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectHematopoietic stem cell transplantation
dc.subjectChronic GVHD
dc.subjectRuxolitinib
dc.subjectEfficacy
dc.titleEfficacy of Ruxolitinib in the management of chronic GVHD
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu